Last reviewed · How we verify
Dexamethasone and Rituximab
Dexamethasone suppresses immune inflammation while rituximab depletes B cells, together reducing pathogenic immune responses.
Dexamethasone suppresses immune inflammation while rituximab depletes B cells, together reducing pathogenic immune responses. Used for Autoimmune conditions responsive to B-cell depletion and corticosteroid therapy (specific indication not publicly detailed for this Phase 3 trial).
At a glance
| Generic name | Dexamethasone and Rituximab |
|---|---|
| Sponsor | Copenhagen University Hospital at Herlev |
| Drug class | Corticosteroid + Monoclonal antibody (combination) |
| Target | Glucocorticoid receptor (dexamethasone); CD20 (rituximab) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone is a corticosteroid that broadly suppresses inflammatory and immune cell activation. Rituximab is a chimeric monoclonal antibody targeting CD20 on B cells, leading to B-cell depletion. In combination, they provide complementary immunosuppression: corticosteroid-mediated anti-inflammation and B-cell-targeted therapy, potentially useful in autoimmune or B-cell-driven conditions.
Approved indications
- Autoimmune conditions responsive to B-cell depletion and corticosteroid therapy (specific indication not publicly detailed for this Phase 3 trial)
Common side effects
- Infection (opportunistic and bacterial)
- Immunosuppression-related complications
- Infusion reactions (rituximab)
- Hyperglycemia (dexamethasone)
- Mood/psychiatric effects (dexamethasone)
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- BNHL-2015 for Children or Adolescents in China (PHASE2, PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (PHASE2)
- Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (PHASE1)
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |